Stock Story -
Health and wellness products company USANA Health Sciences (NYSE:USNA) will be reporting earnings tomorrow after market close. Here's what you need to know.
USANA beat analysts' revenue expectations by 4.1% last quarter, reporting revenues of $221.1 million, down 3% year on year. It was a decent quarter for the company, with an impressive beat of analysts' earnings estimates but underwhelming revenue and earnings guidance for the full year.
Is USANA a buy or sell going into earnings? Find out by reading the original article on StockStory, it's free.
This quarter, analysts are expecting USANA's revenue to decline 8.7% year on year to $226.8 million, in line with the 9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.69 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they are expecting the business to stay the course heading into earnings. USANA has missed Wall Street's revenue estimates three times over the last two years.
Looking at USANA's peers in the consumer staples segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Colgate-Palmolive (NYSE:CL) delivered year-on-year revenue growth of 6.2%, beating analysts' expectations by 2.1%, and General Mills (NYSE:GIS) reported flat revenue, topping Wall Street's consensus estimates by 2.7%. General Mills's stock price was unchanged following the results.
Read the full analysis of Colgate-Palmolive's and General Mills's results on StockStory.
Growth stocks have been quite volatile to start 2024, and while some of the consumer staples stocks have fared somewhat better, they have not been spared, with share price declining 4.3% over the last month. USANA is down 9.4% during the same time and is heading into earnings with an average analyst price target of $56.5 (compared to share price of $43.47).